Elfega Gomez
Family · Chicago, ILNPI 1750888541
Payments from drug & device makers
Across 247 payments — averaging $21.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$842
- AbbVie$593
- Pfizer$502
- Biohaven Pharmaceuticals, Inc.$345
- GSK$317
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,32799%
- Education$781%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 57 | $1,232 |
| Lilly USA, LLC | 36 | $842 |
| AbbVie | 30 | $593 |
| Pfizer | 21 | $502 |
| Biohaven Pharmaceuticals, Inc. | 7 | $345 |
| GSK | 15 | $317 |
| Amgen(2 entities) | 11 | $210 |
| Amarin Pharma, Inc. | 11 | $183 |
| Exact Sciences | 7 | $173 |
| Novartis | 5 | $114 |
| Boehringer Ingelheim | 5 | $108 |
| Esperion Therapeutics, Inc. | 6 | $106 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $90 |
| Bayer | 5 | $87 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $64 |
| E.r. Squibb & Sons, L.L.C. | 3 | $61 |
| Phadia US Inc. | 3 | $50 |
| Redhill Biopharma Inc. | 2 | $45 |
| Cranial Technologies, Inc | 2 | $32 |
| Seqirus USA Inc | 1 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Hologic Sales And Service, LLC | 1 | $24 |
| Johnson & Johnson | 1 | $22 |
| Abbott | 1 | $22 |
| Philips North America LLC | 1 | $18 |
| Corcept Therapeutics | 1 | $14 |
| Almatica Pharma LLC | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$244
How this compares
$5,406 in reported general payments places this provider in the 95th percentile of 4,941 family providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 99 | $173,319 |
| OzempicSemaglutide | 96 | $97,020 |
| JardianceEmpagliflozin | 50 | $59,618 |
| LinzessLinaclotide | 49 | $50,682 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 11 | $43,793 |
| Repatha SureclickEvolocumab | 34 | $30,887 |
| RybelsusSemaglutide | 16 | $30,801 |
| TradjentaLinagliptin | 24 | $23,409 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $22,555 |
| EliquisApixaban | 15 | $18,867 |
| EntrestoSacubitril/Valsartan | 18 | $18,680 |
| VascepaIcosapent Ethyl | 16 | $14,850 |
| XareltoRivaroxaban | 12 | $13,116 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $10,054 |
| BrilintaTicagrelor | 11 | $9,685 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $842 | $173,31999 claims |
| Novo NordiskOzempic, Rybelsus | $1,232 | $127,820112 claims |
| Boehringer IngelheimJardiance, Tradjenta | $108 | $83,02774 claims |
| AbbVieLinzess | $593 | $50,68249 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $317 | $30,61252 claims |
| PfizerEliquis | $502 | $18,86715 claims |
| NovartisEntresto | $114 | $18,68018 claims |
| Johnson & JohnsonXarelto | $22 | $13,11612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,941 family providers in Illinois.
Other family in Chicago
- Ruth CarricoChicago$582K
- Jamie BroganChicago$282K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Brittony CroasdellChicago$192K
- Stephanie Bradley-MillerChicago$156K
- Elizabeth LegorretaChicago$150K
- Staci GorsonChicago$61K
- Allison MoserChicago$60K
- Darcie McDonaughChicago$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.